AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2664664 — intervention group
Group type: EXPERIMENTAL
Intervention: buspirone
Number of subjects: 20
Study 2664664 — intervention group
Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine
Number of subjects: 20
Study 2664664 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 1064434 — intervention group
Group type: EXPERIMENTAL
Intervention: vincristine‐‐prednisone
Number of subjects: 32
Study 1064434 — intervention group
Group type: COMPARATOR
Intervention: cytosine arabinoside‐‐6‐thioguanine
Number of subjects: 32
Study 6251114 — intervention group
Group type: EXPERIMENTAL
Intervention: FK 33824 (0.5 mg i.m.)
Number of subjects: 8
Study 6251114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31577356 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Participation Transition After Stroke (COMPASS) intervention, which includes home modifications and strategy training delivered in the home.
Number of subjects: 180
Study 31577356 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Participation Transition After Stroke (COMPASS) intervention.
Number of subjects: 180
Study 31577356 — intervention group
Group type: COMPARATOR
Intervention: Attentional control group.
Number of subjects: 180
Study 29246769 — intervention group
Group type: EXPERIMENTAL
Intervention: GAIN 3.0 educational program (flipped classroom model with e-learning and live interactive program)
Number of subjects: 416
Study 29246769 — intervention group
Group type: EXPERIMENTAL
Intervention: GAIN 3.0 educational program
Number of subjects: 416
Study 24287689 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide
Number of subjects: 4
Study 23373103 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous furosemide at a dose equivalent to the daily oral dose
Number of subjects: 308
Study 23373103 — intervention group
Group type: COMPARATOR
Intervention: Higher doses of intravenous furosemide
Number of subjects: 308
Study 19925270 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive deviance strategy in the east unit during the second phase (July to September 2008)
Number of subjects: 40
Study 19925270 — intervention group
Group type: COMPARATOR
Intervention: Control unit (west unit) during the second phase
Number of subjects: 40
Study 19925270 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive deviance strategy in the east unit during the second phase
Number of subjects: 40
Study 19925270 — intervention group
Group type: EXPERIMENTAL
Intervention: Both units during the third phase (October to December 2008)
Number of subjects: 40
Study 16916856 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy
Number of subjects: 0
Study 16916856 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training programmes
Number of subjects: 0
Study 16916856 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cognitive-behavioural therapy and exercise training programmes
Number of subjects: 0
Study 16916856 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored treatment approaches
Number of subjects: 0
Study 15738537 — intervention group
Group type: EXPERIMENTAL
Intervention: FU/LV/bevacizumab
Number of subjects: 209
Study 15738537 — intervention group
Group type: COMPARATOR
Intervention: FU/LV/placebo
Number of subjects: 209
Study 11943033 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate sodium (5 mg/day for 2 years and 10 mg/day for the remainder of the study)
Number of subjects: 3685
Study 11943033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3685
Study 11943033 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate sodium
Number of subjects: 3685
Study 9706945 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine system (TD-NICO) 21 mg/d for at least 10 h before anesthesia
Number of subjects: 130
Study 9706945 — intervention group
Group type: COMPARATOR
Intervention: Abstinent group (ABST) with placebo transdermal system
Number of subjects: 130
Study 9706945 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers (SMOK) allowed to smoke until 1-3 h before anesthesia
Number of subjects: 130
Study 9706945 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsmokers (NON-SMOK)
Number of subjects: 130
Study 9706945 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine system (TD-NICO)
Number of subjects: 130
Study 9706945 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers (SMOK)
Number of subjects: 130
Study 7621689 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft jelly capsules containing nonoxynol
Number of subjects: 40
Study 7621689 — intervention group
Group type: COMPARATOR
Intervention: Storage and temperature conditions
Number of subjects: 40
Study 2634032 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led education
Number of subjects: 25
Study 2634032 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher-led education
Number of subjects: 25
Study 2634032 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 25
Study 330289 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcysteine-isoproterenol (AI)
Number of subjects: 0
Study 330289 — intervention group
Group type: COMPARATOR
Intervention: Saline-isoproterenol (SI)
Number of subjects: 0
Study 29080078 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D xenogeneic collagen matrix (CMX)
Number of subjects: 8
Study 29080078 — intervention group
Group type: COMPARATOR
Intervention: Connective tissue graft (CTG)
Number of subjects: 8
Study 27711974 — intervention group
Group type: EXPERIMENTAL
Intervention: Detectable ctDNA 3 months after HSCT
Number of subjects: 88
Study 27711974 — intervention group
Group type: EXPERIMENTAL
Intervention: Detectable ctDNA
Number of subjects: 88
Study 24018349 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training (9-week program)
Number of subjects: 51
Study 24018349 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 51
Study 22917265 — intervention group
Group type: EXPERIMENTAL
Intervention: Click version of the abdominal exam module
Number of subjects: 143
Study 22917265 — intervention group
Group type: COMPARATOR
Intervention: Watch version of the abdominal exam module
Number of subjects: 143
Study 22917265 — intervention group
Group type: COMPARATOR
Intervention: Drag version of the abdominal exam module
Number of subjects: 143
Study 20028833 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week cognitive behavior therapy program for hostility reduction
Number of subjects: 158
Study 20028833 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 158
Study 19244932 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (21 g) with glucose polymer (252 g) for 5 days (CR‐GP)
Number of subjects: 20
Study 19244932 — intervention group
Group type: COMPARATOR
Intervention: Placebo with glucose polymer (252 g) for 5 days (PL‐GP)
Number of subjects: 20
Study 15990747 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate-control therapy
Number of subjects: 0
Study 15990747 — intervention group
Group type: COMPARATOR
Intervention: Rhythm-control therapy
Number of subjects: 0
Study 12950123 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tegafur-uracil plus folinic acid (UFT group)
Number of subjects: 122
Study 12950123 — intervention group
Group type: COMPARATOR
Intervention: Intravenous 5-fluorouracil plus folinic acid (5-FU group)
Number of subjects: 122
Study 12950123 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 122
Study 10904241 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg
Number of subjects: 0
Study 10904241 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 0
Study 10904241 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 40-120 mg
Number of subjects: 0
Study 8738587 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous low-molecular-weight heparin (LMW heparin)
Number of subjects: 1688
Study 8738587 — intervention group
Group type: COMPARATOR
Intervention: Standard heparin (UF heparin)
Number of subjects: 1688
Study 1548522 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (n = 160)
Number of subjects: 613
Study 1548522 — intervention group
Group type: EXPERIMENTAL
Intervention: HER‐2/neu-positive tumors (subset of low-risk lesions without significant in situ component, n = 179)
Number of subjects: 613
Study 1548522 — intervention group
Group type: EXPERIMENTAL
Intervention: HER‐2/neu-negative tumors (subset of low-risk lesions without significant in situ component, n = 179)
Number of subjects: 613
Study 1548522 — intervention group
Group type: COMPARATOR
Intervention: Combined low-risk and high-risk patients not receiving adjuvant therapy (n = 453)
Number of subjects: 613
Study 2993750 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication only
Number of subjects: 174
Study 2993750 — intervention group
Group type: EXPERIMENTAL
Intervention: Active support
Number of subjects: 174
Study 2993750 — intervention group
Group type: COMPARATOR
Intervention: Untreated medical monitoring
Number of subjects: 174
Study 28921862 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg once-daily
Number of subjects: 464
Study 28921862 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg once-daily
Number of subjects: 464
Study 28921862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 464
Study 28921862 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin (both doses)
Number of subjects: 464
Study 28921862 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Number of subjects: 464
Study 27794093 — intervention group
Group type: EXPERIMENTAL
Intervention: PCVA (Physician-Certified Verbal Autopsy)
Number of subjects: 137
Study 27794093 — intervention group
Group type: EXPERIMENTAL
Intervention: InterVA-4 (software for verbal autopsy)
Number of subjects: 137
Study 27794093 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PCVA and InterVA-4
Number of subjects: 137
Study 25015027 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH-LA 40 mg/day
Number of subjects: 489
Study 25015027 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH-LA 60 mg/day
Number of subjects: 489
Study 25015027 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH-LA 80 mg/day
Number of subjects: 489
Study 23129008 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of 150 × 10^6 BMCs
Number of subjects: 120
Study 23129008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 23129008 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of BMCs at day 3
Number of subjects: 120
Study 23129008 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of BMCs at day 7
Number of subjects: 120
Study 23129008 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of BMCs
Number of subjects: 120
Study 23129008 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 120
Study 20337639 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow mesenchymal stem cells injected via the noninfarct-relative artery (right coronary artery, RCA)
Number of subjects: 16
Study 20337639 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow mesenchymal stem cells injected via the infarct-relative artery (left anterior descending branch artery, LAD)
Number of subjects: 16
Study 18270353 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate PEEP strategy (5-9 cm H(2)O); n = 382
Number of subjects: 767
Study 18270353 — intervention group
Group type: COMPARATOR
Intervention: Increased recruitment strategy (PEEP set to reach plateau pressure of 28 to 30 cm H(2)O); n = 385
Number of subjects: 767
Study 15928685 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified pasteurised milk (200 µg folic acid)
Number of subjects: 69
Study 15928685 — intervention group
Group type: COMPARATOR
Intervention: Fortified pasteurised milk
Number of subjects: 69
Study 12721666 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (maximum single dose 200 mg, cumulative daily dose 350 mg)
Number of subjects: 77
Study 12721666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 10533347 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma management program intervention
Number of subjects: 1635
Study 10533347 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1635
Study 8690116 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH-a and recombinant FSH
Number of subjects: 171
Study 8690116 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH-a and urinary FSH
Number of subjects: 171
Study 2069238 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoxygenation for three minutes prior to thiopentone induction
Number of subjects: 100
Study 2069238 — intervention group
Group type: COMPARATOR
Intervention: Room air prior to induction
Number of subjects: 100
Study 6312461 — intervention group
Group type: EXPERIMENTAL
Intervention: pivmecillinam plus pivampicillin (100 mg pivmecillinam plus 125 mg pivampicillin 3-times daily for 7 to 14 days)
Number of subjects: 62
Study 6312461 — intervention group
Group type: COMPARATOR
Intervention: pivampicillin alone (250 mg pivampicillin 3-times daily for 7 to 14 days)
Number of subjects: 62
Study 6312461 — intervention group
Group type: EXPERIMENTAL
Intervention: pivmecillinam plus pivampicillin
Number of subjects: 62
Study 6312461 — intervention group
Group type: COMPARATOR
Intervention: pivampicillin alone
Number of subjects: 62
Study 30895515 — intervention group
Group type: EXPERIMENTAL
Intervention: StatStrip point‐of‐care test (POCT) glucose monitor
Number of subjects: 121
Study 30895515 — intervention group
Group type: COMPARATOR
Intervention: GEM® Premier™ 3000 blood gas analyzer
Number of subjects: 121
Study 29745006 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min of intradialytic exercise (IDEX) in the first hour of treatment
Number of subjects: 12
Study 29745006 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min of intradialytic exercise (IDEX) in the third hour of treatment
Number of subjects: 12
Study 29745006 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control)
Number of subjects: 12
Study 26892910 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 754
Study 26892910 — intervention group
Group type: COMPARATOR
Intervention: Refusal of Nicotine Replacement Therapy (NRT)
Number of subjects: 754
Study 24669988 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Exercise Promotion program (PEP-1)
Number of subjects: 48
Study 24669988 — intervention group
Group type: COMPARATOR
Intervention: Information leaflet (control)
Number of subjects: 48
Study 22611182 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic saphenous vein harvesting (EVH)
Number of subjects: 150
Study 22611182 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard bridging technique (SBT)
Number of subjects: 150
Study 22611182 — intervention group
Group type: COMPARATOR
Intervention: Open vein harvesting (OVH)
Number of subjects: 150
Study 20851230 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate (CMA)
Number of subjects: 59
Study 17437655 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% 10 mL
Number of subjects: 50
Study 17437655 — intervention group
Group type: COMPARATOR
Intervention: Control (saline 0.9%)
Number of subjects: 50
Study 15809943 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-navigated total knee arthroplasty
Number of subjects: 52
Study 15809943 — intervention group
Group type: COMPARATOR
Intervention: Conventional total knee arthroplasty
Number of subjects: 52
Study 11983194 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-tocopherol E (50 I.U./day)
Number of subjects: 39
Study 11983194 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 39
Study 9708526 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (5 mg, 3 times/day, before meals, for 2 weeks)
Number of subjects: 55
Study 7617541 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose terodiline (12.5 mg)
Number of subjects: 20
Study 7617541 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose terodiline (25 mg)
Number of subjects: 20
Study 7617541 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose terodiline (12.5 mg b.i.d. for 14 days)
Number of subjects: 20
Study 7617541 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose terodiline (25 mg b.i.d. for 14 days)
Number of subjects: 20
Study 7617541 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall terodiline treatment
Number of subjects: 20
Study 1322427 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg daily)
Number of subjects: 20
Study 1322427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6327190 — intervention group
Group type: EXPERIMENTAL
Intervention: Veralipride 100 mg per day for 20 days
Number of subjects: 43
Study 6327190 — intervention group
Group type: COMPARATOR
Intervention: Conjugated oestrogens 1.25 mg per day for 20 days
Number of subjects: 43
Study 30193074 — intervention group
Group type: EXPERIMENTAL
Intervention: Basketball-specific high-intensity interval training (HIIT), 10 sessions over 5 weeks
Number of subjects: 24
Study 30193074 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG), continued normal team training routine
Number of subjects: 24
Study 30193074 — intervention group
Group type: EXPERIMENTAL
Intervention: Basketball-specific HIIT
Number of subjects: 24
Study 30193074 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 24
Study 28678622 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.4% carbohydrate mouth rinse (RCHO)
Number of subjects: 15
Study 28678622 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution (RP)
Number of subjects: 15
Study 27198036 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (5µg), Vitamin K (90µg), Calcium (500mg)
Number of subjects: 66
Study 24698174 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention for older adults in rehabilitation after stroke
Number of subjects: 99
Study 22855310 — intervention group
Group type: EXPERIMENTAL
Intervention: BIOPATCH applied to the catheter exit site
Number of subjects: 100
Study 22855310 — intervention group
Group type: COMPARATOR
Intervention: Non-BIOPATCH (no patch applied)
Number of subjects: 100
Study 19898245 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine-clonazepam cotherapy
Number of subjects: 80
Study 19898245 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine monotherapy
Number of subjects: 80
Study 17921424 — intervention group
Group type: EXPERIMENTAL
Intervention: Education program consisting of two 4-hour classroom and two 1-hour on-road sessions focused on common problem areas of older drivers.
Number of subjects: 126
Study 17921424 — intervention group
Group type: COMPARATOR
Intervention: Modules directed at vehicle, home, and environmental safety (Control).
Number of subjects: 126
Study 16291843 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Dye taping for 3 to 5 days
Number of subjects: 105
Study 16291843 — intervention group
Group type: COMPARATOR
Intervention: Control group (no taping)
Number of subjects: 105
Study 16291843 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Dye taping
Number of subjects: 105
Study 12118025 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin and paclitaxel (AT) regimen (doxorubicin 60 mg/m² IV bolus + paclitaxel 175 mg/m² 3-hour infusion)
Number of subjects: 275
Study 12118025 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin and cyclophosphamide (AC) regimen (doxorubicin 60 mg/m² + cyclophosphamide 600 mg/m²)
Number of subjects: 275
Study 9097275 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha treatment for 6 months (Group I)
Number of subjects: 38
Study 9097275 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha treatment for 12 months (Group II)
Number of subjects: 38
Study 9097275 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha treatment for both groups
Number of subjects: 38
Study 8126635 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1 g i.v. single dose)
Number of subjects: 1052
Study 8126635 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (1 g i.v. three doses)
Number of subjects: 1052
Study 2956228 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin+amikacin
Number of subjects: 10
Study 2956228 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin+amikacin
Number of subjects: 10
Study 2956228 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 10
Study 2956228 — intervention group
Group type: COMPARATOR
Intervention: Amikacin alone
Number of subjects: 10
Study 31499010 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone supplementation
Number of subjects: 28
Study 31499010 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 28
Study 29568749 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric exercise (PLY)
Number of subjects: 14
Study 29568749 — intervention group
Group type: COMPARATOR
Intervention: Heavy‐resistance exercise (RES)
Number of subjects: 14
Study 26384466 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Fat Dietary Pattern Intervention
Number of subjects: 48835
Study 23880900 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 109
Study 23880900 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 109
Study 22963751 — intervention group
Group type: EXPERIMENTAL
Intervention: GLM-enriched diet
Number of subjects: 23
Study 19756029 — intervention group
Group type: EXPERIMENTAL
Intervention: B‐GOS (galacto‐oligosaccharide mixture)
Number of subjects: 159
Study 19756029 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 159
Study 18216374 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Herbst appliance (IHA)
Number of subjects: 30
Study 18216374 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated age-matched males with Class II malocclusions)
Number of subjects: 30
Study 16549839 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab infusion (VEGF antibody blockade)
Number of subjects: 0
Study 16549839 — intervention group
Group type: EXPERIMENTAL
Intervention: CD146+ cells
Number of subjects: 0